Puma Biotechnology Patent-Cliff Exposure & CMS Drug Spending Portfolio
Puma Biotechnology (Los Angeles, CA): 1 reconciled FDA prescription therapies, $60.6M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Los Angeles, CA |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2031-01-01 |
| 2024 CMS Total Public Spend | $60.6M |
| 2024 Medicare Part D Spend | $38.4M |
| 2024 Medicaid Spend | $22.2M |
| California HCAI SB 17 Filings | 8 WAC filings (max 24.0% 2-yr change) |